Tamtam Try Tamtam free
Option Care Health logo

Option Care Health account plan

Nationwide home infusion care

At a glance

Option Care Health, the largest independent US home infusion provider, had FY2025 revenue of $5,649.5 million and is being acquired by CD&R and McKesson.

Option Care Health, headquartered in Bannockburn, Illinois, provides home and alternate site infusion services across the US: it supplies drugs and complex compounded solutions for intravenous delivery in patients' homes, infusion suites and clinics, with nursing, monitoring and reimbursement support. It contracts with managed care organizations and other payers, hospitals and health systems, physicians and pharmaceutical manufacturers. FY2025 net revenue was $5,649.5 million (+13.0%) and net income $207.6 million; at December 31, 2025 it had 6,528 full-time and 1,738 part-time employees, including more than 5,000 clinicians. Listed on Nasdaq (OPCH), it agreed on October 5, 2026 to be taken private by affiliates of Clayton, Dubilier & Rice and McKesson for $32.05 per share in cash, with closing expected in the first half of 2027.

Business units

Strategic priorities

Grow site-of-care programs with payers
Option Care has active site-of-care programs with the largest national payers and added five new programs with regional health plans and two with nontraditional payers in 2025, as payers look to lower costs.
Expand rare and orphan therapy platforms
It runs over 20 platforms for rare or limited distribution drugs, with two more starting in 2026; growth vectors named are neurology, autoimmune, dermatology, oncology and rare diseases.
Build out infusion clinics
Over 80 infusion chairs were added in 2025 and five new ambulatory infusion clinics opened in Q2 2026; over 35% of nursing visits now take place in a suite or clinic.
Automation and AI in operations
About 40% of claims are processed without human intervention, and AI is deployed for nurse route and scheduling optimization, delivery routing, patient onboarding and claims.
Commercial reset
Sales resources were realigned on top specialty practices and accounts to expand reach and frequency, with commercial hires from late 2025 expected to gain productivity in the second half of 2026.

Latest results

In Q3 2026 (quarter to September 30, 2026) net revenue was $1,493.5 million, up 4.1%, gross margin 19.1% and net income $57.4 million, up 10.8%. Acute therapies grew high single digits, while chronic grew low single digits as IG/neuro and rare and orphan growth offset a decline in the chronic inflammatory disease (CID) portfolio. Over nine months revenue was $4,286.6 million (+2.5%) and operating cash flow rose to $286.2 million on lower inventory. CID dynamics are still expected to cut 2026 gross profit by about $55 million, and the company withdrew its 2026 guidance when it agreed to the take-private deal.

Investments and deals

Take-private by CD&R and McKesson
Agreed on October 5, 2026 at $32.05 per share, an enterprise value of about $5.8 billion; CD&R will hold about 51% and McKesson will invest about $1.4 billion for about 49%, with a framework for McKesson to later buy CD&R's interest.
Intramed Plus acquisition
Acquired on January 24, 2025 for $117.2 million net of cash; its South Carolina site grew volumes 25% year over year.
Share repurchases
$310.0 million repurchased in 2025 and $167.5 million in the first nine months of 2026, with the authorization raised to $1 billion; buybacks are now frozen by the merger agreement.
Refinancing
The term loan was refinanced in September 2025 at Term SOFR + 1.75% to 2032, and the revolver now provides up to $850.0 million.

Challenges and risks

CID and biosimilar headwind
Stelara biosimilar conversion and CID patient attrition are expected to cut 2026 gross profit by about $55 million, and higher-cost chronic therapies dilute gross margin, which fell to 19.3% in 2025 from 20.3%.
Restrictions while the merger is pending
Acquisitions, capex, financing, pay increases and buybacks need the buyer's consent until closing, which may limit or delay strategic investments.
Payer dependence and rate pressure
The largest payer is about 14% of revenue; payer bidding and consolidation, pricing benchmarks and rate pressure for Medicare Advantage exposure are named risks.
Clinician shortages
Shortages of nurses and pharmacists are a named risk for a business that relies on a nursing team of about 2,700.
Supplier concentration
About 55% of Q3 2026 drug and supply purchases came from three vendors.

What leadership says

“continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care”

John C. Rademacher, President and CEO · CD&R and McKesson acquisition press release, October 6, 2026

“Although I am pleased with our progress in the second quarter, I am not satisfied with our performance.”

John C. Rademacher, President and CEO · Q2 2026 earnings call, July 29, 2026

“we believe the application of artificial intelligence will reduce the cost of healthcare while improving clinician efficiency”

John C. Rademacher, President and CEO · Q2 2026 earnings call, July 29, 2026

“provides immediate cash value for our stockholders”

Harry Kraemer, Chairman · CD&R and McKesson acquisition press release, October 6, 2026

Where a supplier can help

Technology to accelerate deployment
Tied to the automation and AI priority and the CEO's aim to accelerate advanced technology deployment under new owners: claims automation, scheduling, routing and patient onboarding tools.
Clinician recruiting and retention
Tied to the clinician-shortage challenge and the clinic build-out: nurse and pharmacist staffing, scheduling and retention solutions.
Pharma commercialization services
Tied to the rare and orphan platform priority: data, clinical trial support and patient-program services for manufacturers launching limited distribution drugs.
Infusion clinic fit-out
Tied to the clinic build-out: chairs, equipment and site services for new and converted infusion suites, timed around capex limits while the merger is pending.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Option Care Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Option Care Health

What does Option Care Health do?

It provides home and alternate site infusion services, supplying drugs and compounded solutions for intravenous delivery in homes, infusion suites and clinics, with nursing and reimbursement support.

What is Option Care Health's revenue?

FY2025 net revenue was $5,649.5 million, up 13.0%; Q3 2026 net revenue was $1,493.5 million, up 4.1%.

How many employees does Option Care Health have?

At December 31, 2025 it had 6,528 full-time and 1,738 part-time employees, including more than 5,000 clinicians.

Who is acquiring Option Care Health?

Affiliates of Clayton, Dubilier & Rice and McKesson agreed on October 5, 2026 to acquire it for $32.05 per share in cash, with closing expected in the first half of 2027.

Who leads Option Care Health?

John C. Rademacher is President and CEO, Meenal Sethna is CFO, and Harry M. Jansen Kraemer, Jr. is Non-Executive Chairman.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)